Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...

The price continued to rise, reaching $401.49 by June 12 amid an ICO boom but faced a drop to $157.36 by July 16 due to concerns over a crypto bubble. By September 15, it recovered to $253. In 2018, ...